Calafat, MargalidaTorres, PaolaTosca-Cuquerella, JoanSánchez-Aldehuelo, RubénRivero, MontserratIborra, MarisaGonzález-Vivo, MaríaVera, Isabelde Castro, LuisaBujanda, LuisBarreiro-de Acosta, ManuelGonzález-Muñoza, CarlosCalvet, XavierBenítez, José ManuelLlorente-Barrio, MónicaSurís, GerardCañete, FiorellaArias-García, LaraMonfort, DavidCastaño-García, AndrésGarcia-Alonso, Francisco JavierHuguet, José M.Marín-Jímenez, IgnacioLorente, RufoMartín-Cardona, AlbertFerrer, Juan ÁngelCamo, PatriciaGisbert, Javier P.Pajares, RamónGomollón, FernandoCastro-Poceiro, JesúsMorales-Alvarado, JairLlaó, JordinaRodríguez, AndrésRodríguez, CristinaPérez-Galindo, PabloNavarro, MercèJiménez-García, NuriaCarrillo-Palau, MartaBlázquez-Gómez, IsabelSesé, EvaAlmela, PedroRamírez de la Piscina, PatriciaTaxonera, CarlosRodríguez-Lago, IagoCabrinety, LidiaVela, MilagrosMínguez, MiguelMesonero, FranciscoGarcía, María JoséAguas, MariamMárquez, LucíaSilva Porto, MarisolPineda, Juan R.García-Etxebarría, KoldoBertoletti, FedericoBrunet, EduardMañosa, MíriamDomènech, Eugeni2026-01-272026-01-272024-01-01Calafat, M, Torres, P, Tosca-Cuquerella, J, Sánchez-Aldehuelo, R, Rivero, M, Iborra, M, González-Vivo, M, Vera, I, de Castro, L, Bujanda, L, Barreiro-de Acosta, M, González-Muñoza, C, Calvet, X, Benítez, J M, Llorente-Barrio, M, Surís, G, Cañete, F, Arias-García, L, Monfort, D, Castaño-García, A, Garcia-Alonso, F J, Huguet, J M, Marín-Jímenez, I, Lorente, R, Martín-Cardona, A, Ferrer, J Á, Camo, P, Gisbert, J P, Pajares, R, Gomollón, F, Castro-Poceiro, J, Morales-Alvarado, J, Llaó, J, Rodríguez, A, Rodríguez, C, Pérez-Galindo, P, Navarro, M, Jiménez-García, N, Carrillo-Palau, M, Blázquez-Gómez, I, Sesé, E, Almela, P, Ramírez de la Piscina, P, Taxonera, C, Rodríguez-Lago, I, Cabrinety, L, Vela, M, Mínguez, M, Mesonero, F, García, M J, Aguas, M, Márquez, L, Silva Porto, M, Pineda, J R, García-Etxebarría, K, Bertoletti, F, Brunet, E, Mañosa, M & Domènech, E 2024, 'Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents : data from the ENEIDA registry', Therapeutic Advances in Gastroenterology, vol. 17. https://doi.org/10.1177/175628482312217131756-283XPubMedCentral: PMC10771049https://hdl.handle.net/10641/7615Publisher Copyright: © The Author(s), 2024.Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.495595enghttp://creativecommons.org/licenses/by-nc-nd/4.0/adalimumabanti-TNFgolimumabinfliximabswitchulcerative colitisGastroenterologyYesyesjournal articleopen access10.1177/17562848231221713https://www.scopus.com/pages/publications/85182637256https://www.scopus.com/pages/publications/85182637256#tab=citedBy